Altre lingue Senti Biosciences, Inc.

Azioni

SNTI

US81726A1007

Prezzo di chiusura Nasdaq Altri mercati azionari 00:00:00 24/04/2024			Variaz. 5gg	Var. 1 gen.
0,2809 ^USD	-6,37%		-9,39%	-57,44%

21/03	Senti Biosciences, Inc. riporta i risultati degli utili per l'intero anno conclusosi il 31 dicembre 2023	CI
21/03	Senti Biosciences, Inc. riporta i risultati degli utili per il quarto trimestre conclusosi il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Senti Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Earnings Flash (SNTI) SENTI BIOSCIENCES Reports 2023 Revenue $2.6M	21/03
Senti Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights	21/03
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program	05/01
Spark Therapeutics, Inc. Announces Workforce Reduction	05/01
Top Premarket Gainers	22/12
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	22/12
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	22/12
Senti Biosciences, Inc. Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	22/12
Senti Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Earnings Flash (SNTI) SENTI BIOSCIENCES Posts Q3 Revenue $338,000	13/11
Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates	13/11
Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China	06/11
Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China	06/11
Senti Biosciences, Inc. Announces New Strategic Collaboration with Celest Therapeutics Co. Ltd	06/11
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting	31/10/23
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting	31/10/23
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting	27/09/23
Senti Bio to Participate in Upcoming Conferences	26/09/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Senti Biosciences, Inc.

Azioni

SNTI

US81726A1007

Altre lingue

Filtri